Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Christopher P. Cannon, Vlado Perkovic, Rajiv Agarwal, James Baldassarre, George Bakris, David M. Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J.L. Heerspink, Meg J. Jardine, Adeera Levin, Jing Wei Li, Bruce Neal, Carol Pollock, David C. Wheeler, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey

Research output: Contribution to journalLetter

16 Scopus citations
Original languageEnglish (US)
Pages (from-to)407-410
Number of pages4
JournalCirculation
Volume141
Issue number5
DOIs
StatePublished - Feb 4 2020

Keywords

  • SGLT2 inhibitors
  • canagliflozin
  • chronic kidney disease
  • diabetes mellitus, type 2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Jardine, M. J., Levin, A., Li, J. W., Neal, B., Pollock, C., Wheeler, D. C., Zhang, H., Zinman, B., & Mahaffey, K. W. (2020). Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation, 141(5), 407-410. https://doi.org/10.1161/CIRCULATIONAHA.119.044359